Amarin - The Science Of Lipid Therapy (Seite 23)

[lobberland]

Antwort auf Beitrag Nr.: 69.126.203 von Magnetfeldfredy am 23.08.21 16:14:08

Letzte verzweifelte Versuche hier den Anstieg zu stoppen 😊

[Magnetfeldfredy]

Amarin

Let the games begins and burn the fucking shorts!🤠

[bernie55]

Antwort auf Beitrag Nr.: 69.124.319 von Stevo0815 am 23.08.21 13:18:14

Zitat von Stevo0815: Amarin ist eine zickige Aktie. Ich drück mal ein wenig auf die Bremse!
Hoffentlich klappt es diesmal, ich würde es allen mitinvestierten von Herzen gönnen.

Amarin ist eben keine "0-8-15" Aktie .😉

Grüße
bernie55 🙂

[Stevo0815]

Amarin ist eine zickige Aktie. Ich drück mal ein wenig auf die Bremse!
Hoffentlich klappt es diesmal, ich würde es allen mitinvestierten von Herzen gönnen.

[asthmamoah]

Ab Ende der Woche müsste ja ein News Feuerwerk beginnen .... mit diesen zusammen hat dieses hoffentlich einen entsprechenden Einfluss auf den Kurs. Eigentlich ist ja alles nur eine Frage der Zeit 😊

[bernie55]

Hi Fredy,
SuperNews 👍😎👍

Diese sollten doch durchaus Interesse sowohl bei "GROß" als auch " Klein" wecken....

Grüße
bernie55 🙂

[Magnetfeldfredy]

Amarins Comeback wird diese Wochen kommen!

Heute die überragenden statistisch signifikanten Herzinfarktdaten und am Sonntag Vascepa Covid Ergebnisse, das Comeback des Jahres?

Company behind heart drug could have folded after loss in courts. Instead, it goes all-in with risky new plan
Published: Aug. 22, 2021, 9:19 a.m.
Karim Mikhail, President and CEO, Amrian Pharma, Inc.

Karim Mikhail, President and CEO, Amrian Pharma, Inc., Bridgewater, NJ. 08/16/2021Steve Hockstein | For NJ Advance
By George E. Jordan | For NJ Advance Media

For every giant drugmaker like Pfizer, Merck or Johnson & Johnson, whose products are in medicine cabinets around the world, there are countless startups and small biopharmaceutical firms chasing their magic medicine. Some burn out like shooting stars and never make it. Others hit the jackpot with a “One Hit Wonder,” a drug that sets the company on solid footing or makes it a takeover target.

And then there’s the case of Amarin, which has more than 1,000 employees in Bridgewater and Ireland.

Less than two years ago, Wall Street anticipated the firm’s only drug, Vascepa, could become an important new cardiovascular medicine – just as Covid was about to leave millions around the world with heart problems.

Then, in March 2020, U.S federal courts invalidated several patents for Vascepa, opening the door to generic competition and potentially shrinking sales of the company’s once-promising drug.

Amarin’s stock price fell by 50% virtually overnight.

The court rulings could have been a death sentence for a company like Amarin. Instead, it has rebounded with a risky, unusually aggressive strategy for a small drugmaker that markets and sells a single pill.

Karim Mikhail, Amarin’s CEO and a 22-year veteran of Merck, said the company will launch sales of Vascepa next month in the European Union and plans to expand into Asia and Africa next year. The company also has added sales staff to battle generic drugmakers for U.S. sales.

“People who fought for the value that this product brings to the market are not letting go today,” he said. “They risked their careers … to prove a point that this product brings enormous benefit.”

The courts did not question the efficacy or safety of Vascepa, a synthetic version of the omega-3 fatty acid derived from fish oil. The drug accounted for almost all of Amarin’s $614.1 million in revenue last year.

The FDA had approved Vascepa in 2012, reversing decades of mixed results for fish-oil-based drugs. The FDA in late 2019 expanded the drug’s label to allow Amarin to say the drug prevents heart attacks and strokes in people at high cardiovascular risk.

Despite a patent decision that amounted to a huge victory for the generics, they are prohibited from marketing copycat pills to heart patients as a replacement for Vascepa. Nor is the generic version FDA-approved to make the heart health claim.

“We are making every effort to ensure the patient is getting the right product for the right indication,” Mikhail said. “We will do everything to protect that business because it is illegal to substitute.”

Instead of skyrocketing success, Amarin has shifted to playing the long game.

It plans to thread the needle to profitability with overseas sales and fighting off U.S. generic competitors by pushing doctors to prescribe Vascepa to more heart patients. Here in the U.S., it must do so by selling a drug that on average costs 77% more than generics.

J.P. Morgan analyst Jessica Fye still believes Vascepa will be successful, she said in investor notes, but sales will ramp up over 10 years.
Karim Mikhail, President and CEO, Amrian Pharma, Inc.

The Amrian Pharma offices in Bridgewater. 08/16/2021Steve Hockstein | For NJ Advance

Amarin’s stock rallied this month, but it has a long way to go to recover from the tumble since the court rulings. The U.S. Supreme Court last month declined to hear Amarin’s appeal.

In January 2020, shares of AMRN reached $21 per share, which gave the company a market cap over $7 billion. Recently, shares have been trading closer $5, leaving the company’s market cap a little over $2 billion.

This month, former Amarin CEO John Thero was succeeded by Mikhail, Merck’s former chief marketing officer in Europe and emerging markets. His appointment and the expansion of Amarin’s sales staff indicated the company plans to go it alone.

“Investors may be disappointed in the transition and that it may signal no near-term merger and acquisition on the table (which is the clear and primary bull case to the stock),” Jefferies analyst Michael Yee wrote in a recent investor note.

Big pharmaceutical companies typically buy up startups to avoid the risk and expense of drug development. But companies like Amarin are rarely acquisition targets, according to studies by Michael Kinch, director of the Center for Drug Discovery at Washington University in St. Louis.

Kinch found the prime takeover targets are typically cancer treatments or medicines for rare diseases with high barriers for entry and few competitors.

Vascepa joins a long list of cardiovascular drugs over the past two decades dominated by blockbusters marketed by Pfizer, Merck, Schering-Plough and AstraZeneca.

The most commonly prescribed heart medicines are today available as low-cost generics. And generics typically capture 95% of the brand-name’s sales three months after generic drugs hits the market, according to Wall Street analysts.

The generic version of Vascepa, has not experienced that level of success.

So far, generic drugmaker Hikma Pharmaceutical’s copycat version, the only one to launch sales, has captured just 9% of the U.S. market, according to Symphony Health, Amarin’s market research consultant.

Dr. Reddy’s Laboratories, another generic drugmaker that won the court battle against Amarin, has yet to launch sales. Still another, Teva, withdrew its FDA approval to sell generic Vascepa.

Mikhail said Vascepa was notoriously difficult to manufacture and the raw ingredients difficult to acquire in bulk. “Clearly, the generics never thought they would win this case,” he said. “The evidence is they were not ready with supply.”

The FDA says Vascepa’s mechanism in action to reduce stroke and heart attacks is “not completely understood.” Amarin claims the drug has anti-inflammatory properties and it has announced several academic centers are studying Vascepa as a possible treatment for colorectal cancer as well as Covid.

Mikhail said preliminary Covid study data is scheduled for release next week at the European Society of Cardiology Congress.

“You look at what Covid patients die from, they mostly die because of an inflammatory storm,” he said. “If the study is positive, and it has value in delaying progression in Covid patients … that would be incredible.”

It would also give Amarin another escape hatch to deliver shareholder value.

[Magnetfeldfredy]

Amarin

Und hier die überragenden Daten die gerade Recht zur Einführung in Deutschland kommen:

Amarin Reports Data from REDUCE-IT® Showing VASCEPA®/VAZKEPA (Icosapent Ethyl) Significantly Reduces Ischemic Events in Patients with Prior Heart Attacks Presented in Late Breaking Science Session at ESC Congress 2021, Organized by the European Society of Cardiology

Amarin Corporation plc
Mon, August 23, 2021, 9:15 AM
In this article:

VASCEPA found in prespecified and post hoc analyses to reduce first and total primary endpoints by 26% and 35%, respectively, in patients with prior Myocardial Infarction

DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that data adding to the growing body of knowledge on VASCEPA®/VAZKEPA (icosapent ethyl) in patients with prior heart attack, known as myocardial infarction (MI), at risk for major adverse cardiovascular events were delivered in a Late Breaking Science Presentation at ESC Congress 2021, organized by the European Society of Cardiology (ESC), taking place virtually from August 27 – August 30, 2021.

The presentation titled, “Reduction in Ischemic Events, Including Cardiovascular Mortality, with Icosapent Ethyl in Patients with Prior Myocardial Infarction: REDUCE-IT PRIOR MI,” was presented on behalf of all authors by Deepak L. Bhatt, M.D., M.P.H., Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital, Professor of Medicine at Harvard Medical School, and principal investigator of REDUCE-IT® and is available On-Demand beginning today at 3:00 am ET (9:00 am CEST) through the completion of the Congress.

The Late Breaking Science Presentation included both prespecified and post hoc analyses of patients who had prior MI from the REDUCE-IT study (prior to trial randomization) to determine if treatment with VASCEPA (icosapent ethyl) reduced further ischemic events in those subjects.

“The REDUCE-IT PRIOR MI analyses provide valuable data supporting an effective new approach to prevent ischemic events using prescription icosapent ethyl in patients who have had previous heart attacks,” commented Dr. Bhatt. “The benefits in these heart attack patients at-risk for another cardiovascular event are particularly important given these patients are at elevated risk for recurrent cardiovascular problems. These results further strengthen the case for pure eicosapentaenoic acid (EPA) in the form of prescription icosapent ethyl as a key intervention beyond statins for meaningful risk reduction by physicians caring for this high-risk population.”

The investigators concluded that, “Icosapent ethyl 4 g/day significantly reduced first and total primary endpoints of 5-point major adverse cardiovascular event (MACE), comprised of CV death, MI, stroke, coronary revascularization, and hospitalization for unstable angina by 26% and 35%, respectively, in patients with prior MI (P=0.00001 and P=0.0000001, respectively). Icosapent ethyl led to generally robust reductions across the prespecified hierarchy of secondary endpoints, and in sudden cardiac death and cardiac arrest. The benefits of icosapent ethyl in patients with prior MI were consistent in those with or without a history or prior revascularization.”

“The global burden of cardiovascular disease is a growing problem worldwide. For patients with prior MI, the risk of ischemic events is even greater. We are delighted to have these analyses presented at this year’s ESC as they show our prescription icosapent ethyl provides substantial cardiovascular risk reduction in the high-risk REDUCE-IT population, with consistent and significant benefits in patients who have experienced a prior MI,” stated Steven Ketchum, Ph.D., executive vice president and president, research & development and chief scientific officer, Amarin.

Additional REDUCE-IT and icosapent ethyl (EPA)-related topics will be presented at ESC Congress 2021 and can be found at https://digital-congress.escardio.org/ESC-Congress (if registered to ESC Congress).

Dr. Bhatt receives research funding paid to Brigham and Women’s Hospital from Amarin for his role as the Chair of REDUCE-IT.

About Amarin

Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our scientific research foundation to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, and Zug in Switzerland as well as commercial partners and suppliers around the world. We are committed to rethinking cardiovascular risk through the advancement of scientific understanding of the impact on society of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management.

About Cardiovascular Risk

Cardiovascular disease is the number one cause of death in the world. In the United States alone, cardiovascular disease results in 859,000 deaths per year.1 And the number of deaths in the United States attributed to cardiovascular disease continues to rise. In addition, in the United States there are 605,000 new and 200,000 recurrent heart attacks per year (approximately 1 every 40 seconds). Stroke rates are 795,000 per year (approximately 1 every 40 seconds), accounting for 1 of every 19 U.S. deaths. In aggregate, in the United States alone, there are more than 2.4 million major adverse cardiovascular events per year from cardiovascular disease or, on average, 1 every 13 seconds.

Controlling bad cholesterol, also known as LDL-C, is one way to reduce a patient’s risk for cardiovascular events, such as heart attack, stroke or death. However, even with the achievement of target LDL-C levels, millions of patients still have significant and persistent risk of cardiovascular events, especially those patients with elevated triglycerides. Statin therapy has been shown to control LDL-C, thereby reducing the risk of cardiovascular events by 25-35%.2 Significant cardiovascular risk remains after statin therapy. People with elevated triglycerides have 35% more cardiovascular events compared to people with normal (in range) triglycerides taking statins.3,4,5

About REDUCE-IT®

REDUCE-IT was a global cardiovascular outcomes study designed to evaluate the effect of VASCEPA in adult patients with LDL-C controlled to between 41-100 mg/dL (median baseline 75 mg/dL) by statin therapy and various cardiovascular risk factors including persistent elevated triglycerides between 135-499 mg/dL (median baseline 216 mg/dL) and either established cardiovascular disease (secondary prevention cohort) or diabetes mellitus and at least one other cardiovascular risk factor (primary prevention cohort).

REDUCE-IT, conducted over seven years and completed in 2018, followed 8,179 patients at over 400 clinical sites in 11 countries with the largest number of sites located within the United States. REDUCE-IT was conducted based on a special protocol assessment agreement with FDA. The design of the REDUCE-IT study was published in March 2017 in Clinical Cardiology.6 The primary results of REDUCE-IT were published in The New England Journal of Medicine in November 2018.7 The total events results of REDUCE-IT were published in the Journal of the American College of Cardiology in March 2019.8 These and other publications can be found in the R&D section on the company’s website at www.amarincorp.com.

About VASCEPA® (icosapent ethyl) Capsules

VASCEPA (icosapent ethyl) capsules are the first-and-only prescription treatment approved by the U.S. Food and Drug Administration (FDA) comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. VASCEPA was launched in the United States in January 2020 as the first and only drug approved by the U.S. FDA for treatment of the studied high-risk patients with persistent cardiovascular risk after statin therapy. VASCEPA was initially launched in the United States in 2013 based on the drug’s initial FDA-approved indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed over ten million times. VASCEPA is covered by most major medical insurance plans. In addition to the United States, VASCEPA is approved and sold in Canada, Lebanon and the United Arab Emirates. In Europe, in March 2021 marketing authorization was granted to icosapent ethyl in the European Union for the reduction of risk of cardiovascular events in patients at high cardiovascular risk, under the brand name VAZKEPA.

Indications and Limitation of Use (in the United States)
VASCEPA is indicated:

As an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and

established cardiovascular disease or

diabetes mellitus and two or more additional risk factors for cardiovascular disease.

As an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.

The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.

Important Safety Information

VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.

VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter.

It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur.

VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin.

Common adverse reactions in the cardiovascular outcomes trial (incidence ≥3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%), and atrial fibrillation (5% vs 4%).

Common adverse reactions in the hypertriglyceridemia trials (incidence >1% more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%).

Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.

Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding.

Key clinical effects of VASCEPA on major adverse cardiovascular events are included in the Clinical Studies section of the prescribing information for VASCEPA as set forth below:

Effect of VASCEPA on Time to First Occurrence of Cardiovascular Events in Patients with
Elevated Triglyceride levels and Other Risk Factors for Cardiovascular Disease in REDUCE-IT


VASCEPA


Placebo


VASCEPA
vs Placebo

N = 4089
n (%)


Incidence Rate
(per 100 patient years)


N = 4090
n (%)


Incidence Rate
(per 100 patient years)


Hazard Ratio
(95% CI)

Primary composite endpoint

Cardiovascular death, myocardial infarction, stroke, coronary revascularization, hospitalization for unstable angina (5-point MACE)


705
(17.2)


4.3


901
(22.0)


5.7


0.75
(0.68, 0.83)

Key secondary composite endpoint

Cardiovascular death, myocardial infarction, stroke (3-point MACE)


459
(11.2)


2.7


606
(14.8)


3.7


0.74
(0.65, 0.83)

Other secondary endpoints

Fatal or non-fatal myocardial infarction


250
(6.1)


1.5


355
(8.7)


2.1


0.69
(0.58, 0.81)

Emergent or urgent coronary revascularization


216
(5.3)


1.3


321
(7.8)


1.9


0.65
(0.55, 0.78)

Cardiovascular death [1]


174
(4.3)


1.0


213
(5.2)


1.2


0.80
(0.66, 0.98)

Hospitalization for unstable angina [2]


108
(2.6)


0.6


157
(3.8)


0.9


0.68
(0.53, 0.87)

Fatal or non-fatal stroke


98
(2.4)


0.6


134
(3.3)


0.8


0.72
(0.55, 0.93)

[1] Includes adjudicated cardiovascular deaths and deaths of undetermined causality.
[2] Determined to be caused by myocardial ischemia by invasive/non-invasive testing and requiring emergent hospitalization.

FULL U.S. FDA-APPROVED VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM.

Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including beliefs about the world-wide market potential for VASCEPA; expectations regarding financial metrics and performance such as prescription growth, revenue growth, operating expenses, inventory purchases, and managed care coverage for VASCEPA, including the impact of the COVID-19 pandemic, the disappointing outcome of patent litigation and the launch of generic competition on these metrics; beliefs that Amarin is well positioned to deliver on its goals to grow VASCEPA in the U.S. and beyond; beliefs about patient needs for VASCEPA; effects of the COVID-19 pandemic on Amarin's operations and on the healthcare industry more broadly, which effects continue to be fluid; beliefs that Amarin's strategy for reducing the effects of cardiovascular disease is sound and that Amarin is efficiently reaching physicians, payors, pharmacists and patients; plans for Amarin's go-to-market model; the timing and outcome of regulatory reviews, recommendations and approvals and related reimbursement decisions and commercial launches in Europe, the China region and elsewhere; plans for Amarin's expected launch of VASCEPA directly in major markets in Europe, directly and indirectly; beliefs about the cardioprotective and other benefits of VASCEPA; beliefs about the strength of data in market access dossiers and other reports; expectations for the timing, effectiveness and outcome of promotional activities, including patient-oriented campaigns, conference and posted presentations and education of healthcare professionals; commercial and international expansion, prescription growth and revenue growth and future revenue levels, including the contributions of sales representatives and the new leadership team; beliefs that Amarin's current resources are sufficient to fund projected operations; ongoing patent litigation efforts; and the impact of the COVID-19 pandemic on all of the forgoing. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Amarin's ability to effectively commercialize VASCEPA and maintain or grow market share will depend in part on Amarin’s ability to continue to effectively finance its business, VASCEPA approval in geographies outside the U.S., efforts of third parties, Amarin’s ability to create and increase market demand for VASCEPA through education, marketing and sales activities, to achieve broad market acceptance of VASCEPA, to receive adequate levels of reimbursement from third-party payers, to develop and maintain a consistent source of commercial supply at a competitive price, to comply with legal and regulatory requirements in connection with the sale and promotion of VASCEPA and to secure, maintain and defend its patent protection for VASCEPA. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: the possibility that VASCEPA may not receive regulatory approval in the China region or other geographies on the expected timelines or at all, the risk that additional generic versions of VASCEPA will enter the market and that generic versions of VASCEPA will achieve greater market share and more commercial supply than anticipated, particularly in light of the recent and disappointing outcome of Amarin's litigation against two generic drug companies and subsequent requests for appeal; the risk that the scope and duration of the COVID-19 pandemic will continue to impact access to and sales of VASCEPA; the risk that Amarin has overestimated the market potential for VASCEPA in the U.S., Europe and other geographies; risks associated with Amarin's expanded enterprise; uncertainties associated generally with research and development, clinical trials and related regulatory approvals; the risk that sales may not meet expectations and related cost may increase beyond expectations; the risk that patents may be determined to not be infringed or not be valid in patent litigation and applications may not result in issued patents sufficient to protect the VASCEPA franchise. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including Amarin’s quarterly report on Form 10-Q for the quarter ended June 30, 2021, filed on or about the date hereof. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin undertakes no obligation to update or revise the information contained in its forward looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate.

Availability of Other Information About Amarin

Investors and others should note that Amarin communicates with its investors and the public using the company website (www.amarincorp.com), the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Amarin Contact Information
Investor Inquiries:
Investor Relations
Amarin Corporation plc
In U.S.: [phone]
[e-mail] (investor inquiries)

Solebury Trout
[e-mail]

Media Inquiries:
Communications
Amarin Corporation plc
In U.S.: [phone]
[e-mail] (media inquiries)

AMARIN, REDUCE-IT, VASCEPA and VAZKEPA are trademarks of Amarin Pharmaceuticals Ireland Limited. VAZKEPA is a registered trademark in Europe and other countries and regions and is pending registration in the United States.

1 American Heart Association. Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association. Circulation. 2020;141:e139-e596.
2 Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72(3):330-343.
3 Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease. Am J Cardiol. 2016;118:138-145.
4 Toth PP, Granowitz C, Hull M, et al. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: A real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J Am Heart Assoc. 2018;7(15):e008740.
5 Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease - New insights from epidemiology, genetics, and biology. Circ Res. 2016;118:547-563.
6 Bhatt DL, Steg PG, Brinton E, et al., on behalf of the REDUCE-IT Investigators. Rationale and Design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial. Clin Cardiol. 2017;40:138-148.
7 Bhatt DL, Steg PG, Miller M, et al., on behalf of the REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:11-22.
8 Bhatt DL, Steg PG, Miller M, et al., on behalf of the REDUCE-IT investigators. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. J Am Coll Cardiol. 2019;73:2791-2802.


GlobeNewswire

[Magnetfeldfredy]

Amarin

I smell double digits, diese Daten und die Covid Erbebnisse könnten Amarin wieder in die Zweistelligkeit führen, unglaublich gute Daten, dazu Pfizer mit einem Fuss im kanadischen Markt als Hinweis der Komplettübernahme?

Amarin announces new data on VASCEPA/VAZKEPA presented at ESC conference 08/16 AMRN Amarin Corporation announced that new data that add to the growing body of knowledge on VASCEPA/VAZKEPA in patients at risk for major adverse cardiovascular events will be presented at ESC Congress 2021, organized by the European Society of Cardiology, or ESC, being held virtually from August 27 - August 30, 2021. These and other new findings will be presented in two Late-Breaking Science presentations and five e-Poster presentations from a variety of international academic collaborators based on research or analyses supported by Amarin. "Given the growing global burden of cardiovascular disease, we are pleased that new data is being presented at this year's ESC Congress in support of the clinical efficacy and underlying scientific rationale for VASCEPA/VAZKEPA to address residual cardiovascular risk. These presentations are particularly timely as we will soon initiate our European launch, starting in Germany, and these data amplify the potential for VASCEPA/VAZKEPA to address heart health in at-risk patients," said Karim Mikhail, Amarin's president and chief executive officer. "We are also looking forward to the first readout from PREPARE-IT 1, part of a larger investigator-initiated study program, looking at the potential benefits of VASCEPA/VAZKEPA for the prevention of COVID-19 in people at risk of exposure to the infection. With COVID-19 continuing to spread due to variants as well as low vaccine rates globally, these data could provide valuable insights in the ongoing fight against this pandemic."

Read more at:
https://thefly.com/n.php?id=3357716

[bernie55]

Antwort auf Beitrag Nr.: 69.067.724 von bernie55 am 16.08.21 22:03:27

Zitat von bernie55: ....Kommentar zu den Präsentationen auf dem ESC 2021 von Karim Mikhail, Präsident und Chief Executive Officer von Amarin ....

"Angesichts der zunehmenden globalen Belastung durch Herz-Kreislauf-Erkrankungen freuen wir uns, dass auf dem diesjährigen ESC-Kongress neue Daten vorgestellt werden, die die klinische Wirksamkeit und die zugrundeliegenden wissenschaftlichen Überlegungen für VASCEPA/VAZKEPA zur Behandlung des kardiovaskulären Restrisikos untermauern. Diese Präsentationen kommen besonders zur rechten Zeit, da wir bald mit der Markteinführung in Europa beginnen werden, zunächst in Deutschland, und diese Daten das Potenzial von VASCEPA/VAZKEPA für die Herzgesundheit von Risikopatienten verstärken",

"Wir freuen uns auch auf die ersten Ergebnisse der PREPARE-IT 1-Studie, die Teil eines grösseren, von Prüfärzten initiierten Studienprogramms ist und den potenziellen Nutzen von VASCEPA/VAZKEPA für die Prävention von COVID-19 bei Menschen mit einem Risiko für diese Infektion untersucht. Angesichts der anhaltenden Ausbreitung von COVID-19 aufgrund von Varianten und der weltweit niedrigen Impfstoffraten könnten diese Daten wertvolle Erkenntnisse für den laufenden Kampf gegen diese Pandemie liefern".

Übersetzt mit Translator

https://finance.yahoo.com/news/latest-clinical-research-eval…